Read the small print
What has actually been shown in people?
Place the claim beside the kind of study that supports it.
FDA—the Food and Drug Administration—handles US reviews of medicines.
- Human studies
About 80 people received BPC-157 in total across five human studies identified in the FDA’s review, checked on 28 September 2026.
Only two compared BPC-157 against a dummy treatment, and neither was available as a full published paper.
- Animal experiments
A rat study reported better healing after cut Achilles tendons, but that is an animal finding rather than a result in people.
- A trial entry
A study plan tells you what investigators intend to test. Look for reported findings before treating it as an answer.
Does it heal injuries in people?
By the check on 28 September 2026, no injury trial had reported results comparing BPC-157 against a dummy treatment.
One knee-pain report looked back at patient records, and most patients given BPC-157 alone said they improved.
It had no separate group of patients without BPC-157 to compare them with, so it cannot show that BPC-157 caused the improvement.
That leaves a useful question for an offer: “Which finding supports the benefit you mean, for the problem I have?”
Read a small report with its limits attached
The FDA judged the bowel-disease trial data inadequate to support BPC-157’s effectiveness and safety for ulcerative colitis, a type of bowel disease.
Insufficient evidence is a reason to leave the claim unsettled. It does not establish that a treatment works or that it cannot work.